Showing results (191-200 of 660) with videos related to
Sort By:
Pageof 66
Nature Cancer|February 4, 2022
Mature tertiary lymphoid structures predict immune checkpoint inhibitor efficacy in solid tumors independently of PD-L1 expressionLucile Vanhersecke, Maxime Brunet, Jean-Philippe Guégan, et al.Nature Cancer|April 22, 2022
Therapeutic targeting of the mevalonate-geranylgeranyl diphosphate pathway with statins overcomes chemotherapy resistance in small cell lung cancerChenchen Guo, Ruijie Wan, Yayi He, et al.Nature Cancer|April 22, 2022
KMT2C deficiency promotes small cell lung cancer metastasis through DNMT3A-mediated epigenetic reprogrammingFeifei Na, Xiangyu Pan, Jingyao Chen, et al.Nature Cancer|April 8, 2022
Concurrent delivery of immune checkpoint blockade modulates T cell dynamics to enhance neoantigen vaccine-generated antitumor immunityLongchao Liu, Jiahui Chen, Hongyi Zhang, et al.Nature Cancer|April 28, 2022
Molecular pathogenesis and systemic therapies for hepatocellular carcinomaJosep M Llovet, Roser Pinyol, Robin K Kelley, et al.Nature Cancer|April 28, 2022
MYCN mediates cysteine addiction and sensitizes neuroblastoma to ferroptosisHamed Alborzinia, Andrés F Flórez, Sina Kreth, et al.Nature Cancer|April 19, 2022
Phosphate dysregulation via the XPR1-KIDINS220 protein complex is a therapeutic vulnerability in ovarian cancerDaniel P Bondeson, Brenton R Paolella, Adhana Asfaw, et al.Nature Cancer|March 22, 2022
Potent suppression of neuroendocrine tumors and gastrointestinal cancers by CDH17CAR T cells without toxicity to normal tissuesZijie Feng, Xin He, Xuyao Zhang, et al.Nature Cancer|April 5, 2022
Outcomes of COVID-19 and risk factors in patients with cancerManju Sengar, Girish Chinnaswamy, Priya Ranganathan, et al.Nature Cancer|March 8, 2022
An anti-PD-1-GITR-L bispecific agonist induces GITR clustering-mediated T cell activation for cancer immunotherapySarah Chan, Nicole Belmar, Sun Ho, et al.Pageof 66